Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Heartbeam, Inc. (BEAT) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $0.42, with a market capitalisation of $22.87M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.39 to $4.00. This page covers its latest market performance, valuation, price trends and company information.
$22.87M | |
$0.41 | |
$80.92 | |
$0.39 | |
$0.43 | |
82.10K | |
667.95K | |
-- | |
$4.00 | |
$0.39 | |
-- | |
-- |
Heartbeam, Inc. (BEAT) is trading at $0.42 in pre-market trading as of 2026-09-16 13:12:00, down 2.35% ($0.01) from the previous close of $0.43
Pre-market trading shows how investors are pricing BEAT before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Heartbeam, Inc. (BEAT) moved from $0.43 to $0.42, representing a decline of 2.76% ($0.01).
The stock traded between $0.39 and $0.46 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 414.04 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.7%
BEAT is currently trading at $0.42, placing it 0.7% of the way from its 52-week low of $0.39 to its 52-week high of $4.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Heartbeam, Inc. (BEAT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.